Quick Order

Human Antithrombin III/ATIII Gene ORF cDNA clone expression plasmid, C-Flag tag

DatasheetReviewsProtocols
Description: Active  
Expression host: Human Cells  
  • Slide 1
10142-H08H-20
10142-H08H-10
20 µg 
10 µg 
Add to Cart
Description: Active  
Expression host: Human Cells  
  • Slide 1
90042-C08H-50
90042-C08H-20
90042-C08H-10
50 µg 
20 µg 
10 µg 
Add to Cart
Reactivity: Human  
Application: ELISA  
    10142-RP02-50
    10142-RP02-200
    10142-RP02-100
    50 µg 
    200 µg 
    100 µg 
    Add to Cart
    Reactivity: Human  
    Application: ELISA  
      10142-R023-50
      10142-R023-100
      50 µg 
      100 µg 
      Add to Cart
      Reactivity: Human  
      Application: ELISA  
        10142-RP01-400
        10142-RP01-200
        10142-RP01-100
        400 µg 
        200 µg 
        100 µg 
        Add to Cart

        Antithrombin III/ATIII cDNA ORF CloneRelated Products

        Related Products

        Featured Reagent Products

        Antithrombin III/ATIII cdna-clone Background

        SerpinC1, also known as antithrombin III (AT III), is a member of the serpin superfamily of serine protease inhibitors, and has been found to be a marker for disseminated intravascular coagulation (DIC) and to be of prognostic significance in septic patients. SerpinC1 synthesized in the liver is the principal plasma serpin of blood coagulation proteases and inhibits thrombin and other factors such as Xa by the formation of covalently linked complexes. Thus it is one of the most important coagulation inhibitors and the fundamental enzyme for the therapeutical action of heparin. In common with SerpinA5 and D1, the inhibitory activity of SerpinC1 undergoes a dramatic increase in the presence of heparin and other glycosaminoglycans. ATIII mediates the promotion of prostaglandin release, an inhibitor of leucocyte activation and downregulator of many proinflammatory cytokines. Antithrombin III exerts anti-inflammatory properties in addition to its anti-coagulative mechanisms. In animal models of sepsis, ATIII affected cytokine plasma concentrations with a decrease of pro-inflammatory cytokines. The deficiency or functional abnormality of ATIII may result in an increased risk of thromboembolic disease, such as deep vein thrombosis and pulmonary embolism. In addition, it has been reported that SerpinC1 can alter or influence inflammatory processes via inhibition of NF-κB activation or actin polymerization.

        Human Antithrombin III/ATIII cdna-clone References
      • de Sousa JC, et al. (1991) Antithrombin III. Physiologic, physiopathologic and laboratory aspects. Rev Port Cardiol. 10(9): 693-9.
      • Totzke G, et al. (2001) Antithrombin III enhances inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Cell Immunol. 208(1): 1-8.
      • Ostermann H. (2002) Antithrombin III in Sepsis. New evidences and open questions. Minerva Anestesiol. 68(5): 445-8.
      • Caglikulekci M, et al. (2004) Effect of antithrombin-III (AT-III) on intestinal epithelium changes related to obstructive icterus: experimental study in rats. Ann Chir. 129(5): 273-7.
      • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"